Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous leukemia (CML) is a pluripotent stem cell dise...
Saved in:
Main Authors: | Emole J, Talabi T, Pinilla-Ibarz J |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/781e9f4f539e475b828a4cf785a7d206 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
by: Muhammad Darwin Prenggono, et al.
Published: (2021) -
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
by: Archibald M, et al.
Published: (2016) -
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
by: Yundeok Kim, et al.
Published: (2021) -
Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
by: Maiko Matsushita
Published: (2021) -
Isolation of Mycobacterium branderi, an unusual species from an acute myelogenous leukemia patient
by: Majid Marjani, et al.
Published: (2014)